Last reviewed · How we verify
NCT06785454
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
Phase 2 trial testing Lorundrostat in Obstructive Sleep Apnea in 48 participants. Completed in 29 December 2025.
17 December 2025
Quick facts
| Lead sponsor | Mineralys Therapeutics Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 28 February 2025 |
| Primary completion | 17 December 2025 |
| Estimated completion | 29 December 2025 |
| Sites | 27 locations across United States |
Drugs / interventions tested
- Lorundrostat — full drug profile →
- Placebo
Conditions studied
- Obstructive Sleep Apnea — all drugs for Obstructive Sleep Apnea →
- Hypertension — all drugs for Hypertension →
Sponsor
Mineralys Therapeutics Inc. — full company profile →
Who can join
Adults 18 to 75, any sex, with Obstructive Sleep Apnea or Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea (OSA) and hypertension.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06785454
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obstructive Sleep Apnea
Currently open trials in the same condition.
- NCT07195253 — Oro-myofunctional Characteristics and Obstructive Sleep Apnea in Infants With Down Syndrome · recruiting
- NCT07273019 — Tongue Muscular Assessment in Children With Sleep Disordered Breathing · NA · recruiting
- NCT07447011 — Glaucoma Respsosne to Lifestyle Corrections in Sleep Apnea · NA · recruiting
- NCT07397780 — RPMO2 Oximeter Accuracy During Sleep 1 Trial · active not recruiting
- NCT06698809 — Obstructive Sleep Apnea Therapeutic Intervention for REsiDual Sleepiness · NA · recruiting
Other Mineralys Therapeutics Inc. trials
Trials by the same sponsor.
- NCT06150924 — Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With H · Phase 2 · completed
- NCT06153693 — Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension · Phase 3 · completed
- NCT05769608 — A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized An · Phase 2 · completed
- NCT05001945 — Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06785454 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mineralys Therapeutics Inc.
- Last refreshed: 13 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06785454.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing